Article
Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.
JCO precision oncology - 1 Sept 2023
Meric-Bernstam Funda, Rothe Michael, Mangat Pam K, Garrett-Mayer Elizabeth, Gutierrez Rodolfo, Ahn Eugene R, Cannon Timothy L, Powell Steven, Krauss John C, Reynolds Christopher M, von Mehren Margaret, Behl Deepti, Calfa Carmen J, Duvivier Herbert L, Kaplan Henry G, Livingston Michael B, Sharma Manish R, Urba Walter J, Grantham Gina N, Hinshaw Dominique C, Gregory Abigail, Halabi Susan, Schilsky Richard L
Abstract excerpt
PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket study evaluating antitumor activity of commercially available targeted agents in patients with advanced cancers with genomic alterations known to be drug targets. The results in a cohort of patients with solid tumors with BRAF mutations treated with cobimetinib plus vemurafenib are reported. METHODS: Eligible patients had...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.